• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by MEDIFAST INC

    7/10/24 1:14:41 PM ET
    $MED
    Packaged Foods
    Consumer Staples
    Get the next $MED alert in real time by email
    SC 13G/A 1 tv0028-medifastinc.htm SCHEDULE 13G/A medifastinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 10)*

    Name of issuer:  Medifast Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  58470H101

    Date of Event Which Requires Filing of this Statement: June 28, 2024

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  58470H101

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    10,639

    7.  SOLE DISPOSITIVE POWER

    708,753

    8.  SHARED DISPOSITIVE POWER

    14,561

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    723,314

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    6.61%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Medifast Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    100 International Drive, 18th Floor
    Baltimore, MD 21202

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    58470H101

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  July 10, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $MED alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MED

    DatePrice TargetRatingAnalyst
    11/5/2024$16.50 → $17.00Underperform → Neutral
    DA Davidson
    6/5/2024$25.00 → $17.50Neutral → Underperform
    DA Davidson
    10/13/2023$82.00Equal-Weight
    Stephens
    11/4/2022$278.00 → $106.00Buy → Neutral
    DA Davidson
    8/4/2022$345.00 → $150.00Buy → Hold
    Jefferies
    2/24/2022$349.00 → $341.00Buy
    DA Davidson
    11/8/2021$395.00 → $349.00Buy
    DA Davidson
    More analyst ratings

    $MED
    SEC Filings

    View All

    MEDIFAST INC filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - MEDIFAST INC (0000910329) (Filer)

    6/1/26 8:59:46 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    MEDIFAST INC filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MEDIFAST INC (0000910329) (Filer)

    5/26/26 4:26:14 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Amendment: SEC Form SCHEDULE 13G/A filed by MEDIFAST INC

    SCHEDULE 13G/A - MEDIFAST INC (0000910329) (Subject)

    5/14/26 5:05:23 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    $MED
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Medifast Confirms Appointment of Nicholas Johnson as Chief Executive Officer

    Johnson will succeed Dan Chard as CEO; Chard to remain Chairman of the Board Medifast, Inc. (NYSE:MED) today announced that its Board of Directors has formally appointed Nicholas Johnson as Chief Executive Officer, effective June 1, 2026. Johnson will succeed Dan Chard as CEO, who will continue to serve as Chairman of the Board. The appointment follows the leadership transition plan that the company disclosed in January and reflects the Board's confidence in Johnson's leadership and the company's strategic direction. Chard will remain actively engaged as Chairman of the Board, supporting Johnson and the leadership team while continuing to provide strategic oversight. "Nick has been a

    5/26/26 4:05:00 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    The Human Layer in Weight Management: What OPTAVIA's Coaching Model Is Built to Do

    A randomized controlled trial published in Obesity Science & Practice found that clients on the OPTAVIA Optimal Weight 5 & 1 Plan® who worked with a coach lost significantly more weight and fat than those who attempted the program without coaching support (Arterburn LM, et al., 2019)Higher retention in a weight management program is directly correlated with more significant weight loss outcomes, per a 2024 systematic review and meta-analysisOPTAVIA coaches complete a program-specific education curriculum and must pass a certification exam before supporting participantsIndependent research commissioned by OPTAVIA found that 96% of Americans recognize lifestyle changes are essential for weight

    5/21/26 7:00:00 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    Weight Loss Coaching vs. App-Only Programs: What Published Research Shows About Long-Term Outcomes

    70% of users discontinued use of lifestyle behavior and health apps within the first 100 days (Kidman PG, et al., 2024)Early weight loss at week four is a strong predictor of clinically relevant outcomes, with research identifying additional counseling and support as key for those showing lower early progress (Coleman CD, et al., 2023)Accountability and self-monitoring are among the most commonly reported factors in sustaining weight loss results, according to a research survey of OPTAVIA coaches and clients (Coleman CD, et al., 2022)In a peer-reviewed clinical trial, participants working with a coach lost up to 10 times more weight and 17 times more fat, and achieved a 14% reduction in visc

    5/21/26 7:00:00 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    $MED
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Medifast upgraded by DA Davidson with a new price target

    DA Davidson upgraded Medifast from Underperform to Neutral and set a new price target of $17.00 from $16.50 previously

    11/5/24 7:48:00 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    Medifast downgraded by DA Davidson with a new price target

    DA Davidson downgraded Medifast from Neutral to Underperform and set a new price target of $17.50 from $25.00 previously

    6/5/24 7:15:11 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    Stephens initiated coverage on Medifast with a new price target

    Stephens initiated coverage of Medifast with a rating of Equal-Weight and set a new price target of $82.00

    10/13/23 7:41:39 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    $MED
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Schlackman Scott bought $62,950 worth of shares (5,000 units at $12.59), increasing direct ownership by 20% to 30,549 units (SEC Form 4)

    4 - MEDIFAST INC (0000910329) (Issuer)

    5/12/26 7:10:46 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Chairman & CEO Chard Daniel R bought $5,003 worth of shares (381 units at $13.13) (SEC Form 4)

    4 - MEDIFAST INC (0000910329) (Issuer)

    6/17/25 6:20:00 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Thomas Andrea B bought $3,471 worth of shares (50 units at $68.89), increasing direct ownership by 0.81% to 6,253 units (SEC Form 4)

    4 - MEDIFAST INC (0000910329) (Issuer)

    11/9/23 8:20:19 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    $MED
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rose Jeffrey Matthew was granted 18,419 shares (SEC Form 4)

    4 - MEDIFAST INC (0000910329) (Issuer)

    5/28/26 7:34:17 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Director Kiai Parsa was granted 19,317 shares (SEC Form 4)

    4 - MEDIFAST INC (0000910329) (Issuer)

    5/28/26 7:33:41 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Director Thomas Andrea B was granted 11,680 shares, increasing direct ownership by 49% to 35,697 units (SEC Form 4)

    4 - MEDIFAST INC (0000910329) (Issuer)

    5/28/26 7:33:01 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    $MED
    Leadership Updates

    Live Leadership Updates

    View All

    Medifast Confirms Appointment of Nicholas Johnson as Chief Executive Officer

    Johnson will succeed Dan Chard as CEO; Chard to remain Chairman of the Board Medifast, Inc. (NYSE:MED) today announced that its Board of Directors has formally appointed Nicholas Johnson as Chief Executive Officer, effective June 1, 2026. Johnson will succeed Dan Chard as CEO, who will continue to serve as Chairman of the Board. The appointment follows the leadership transition plan that the company disclosed in January and reflects the Board's confidence in Johnson's leadership and the company's strategic direction. Chard will remain actively engaged as Chairman of the Board, supporting Johnson and the leadership team while continuing to provide strategic oversight. "Nick has been a

    5/26/26 4:05:00 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Medifast Announces Planned Leadership Transition

     Nicholas Johnson Appointed President, and Expected to Succeed Dan Chard as CEO in June 2026; Chard to Remain Chairman Medifast, Inc. (NYSE:MED) today announced a planned leadership transition designed to provide continuity and stability as the company continues its evolution toward metabolic health. Medifast Chairman & Chief Executive Officer Dan Chard has informed the Board of Directors that he plans to step down as Chief Executive Officer in June 2026. Chard will continue to serve as Chairman of the Board following the transition. The Board has appointed Medifast's Chief Field Operations Officer Nicholas Johnson as President of Medifast, effective immediately. Johnson will work clo

    1/5/26 9:00:00 AM ET
    $MED
    Packaged Foods
    Consumer Staples

    KKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, June 7, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from the S

    6/7/24 6:09:00 PM ET
    $ADTN
    $ALTR
    $ATNI
    Telecommunications Equipment
    Utilities
    Computer Software: Prepackaged Software
    Technology

    $MED
    Financials

    Live finance-specific insights

    View All

    Medifast Announces First Quarter 2026 Financial Results

    Medifast (NYSE:MED), the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system, today reported results for the first quarter ended March 31, 2026. First Quarter 2026 Revenue of $76.0 million, with revenue per active earning coach of $5,432 Independent active earning coaches of 14,000 Net loss of $2.1 million, or $0.19 per diluted share ("EPS") Cash, Cash Equivalents, and Investment Securities of $168.9 million with no debt "We are encouraged by the continued progress we are seeing as we execute our metabolic health strategy, including a second consecutive quarter of year-over-year coach productivity growth, strong coach leadership

    5/4/26 4:05:00 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Medifast to Announce Financial Results for the First Quarter Ended March 31, 2026

    Medifast (NYSE:MED), the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system, will announce financial results for the quarter ended March 31, 2026 on Monday, May 4, 2026, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, Nick Johnson, President, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on May 4, 2026. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com or

    4/20/26 4:05:00 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    Medifast Announces Fourth Quarter and Full Year 2025 Financial Results

    Medifast (NYSE:MED), the health and wellness company known for its science-backed, coach-guided lifestyle system, today reported results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Revenue of $75.1 million, with revenue per active earning coach of $4,664 Independent active earning coaches of 16,100 Net loss of $18.1 million, or $1.65 per diluted share ("EPS"), which includes the tax provision charge to establish a non-cash valuation allowance on the Company's deferred tax balance of $12.1 million (or $1.10 per diluted share) Cash, cash equivalents, and investment Securities of $167.3 million and no debt Full Year 2025 Revenue of $385

    2/17/26 4:05:00 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    $MED
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by MEDIFAST INC

    SC 13G/A - MEDIFAST INC (0000910329) (Subject)

    7/10/24 1:14:41 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    SEC Form SC 13G filed by MEDIFAST INC

    SC 13G - MEDIFAST INC (0000910329) (Subject)

    7/1/24 4:18:04 PM ET
    $MED
    Packaged Foods
    Consumer Staples

    SEC Form SC 13G/A filed by MEDIFAST INC (Amendment)

    SC 13G/A - MEDIFAST INC (0000910329) (Subject)

    2/13/24 10:36:09 AM ET
    $MED
    Packaged Foods
    Consumer Staples